BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37958942)

  • 1. An Activated Dendritic-Cell-Related Gene Signature Indicative of Disease Prognosis and Chemotherapy and Immunotherapy Response in Colon Cancer Patients.
    Ouyang Y; Yu M; Liu T; Suo M; Qiao J; Wang L; Li N
    Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a novel choline metabolism-related signature to predict prognosis, immune landscape, and chemotherapy response in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Liu Y; Xie J; Xie J; Xie Y
    Front Immunol; 2022; 13():1038927. PubMed ID: 36451813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Novel Prognostic Risk Model for Cervical Cancer Based on Immune Checkpoint HLA-G-Driven Differentially Expressed Genes.
    Xu HH; Wang HL; Xing TJ; Wang XQ
    Front Immunol; 2022; 13():851622. PubMed ID: 35924232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
    Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
    [No Abstract]   [Full Text] [Related]  

  • 5. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of a Tumor Microenvironment-Related Gene Signature Indicative of Disease Prognosis and Treatment Response in Colon Cancer.
    Chen W; Huang J; Xiong J; Fu P; Chen C; Liu Y; Li Z; Jie Z; Cao Y
    Oxid Med Cell Longev; 2021; 2021():6290261. PubMed ID: 34497681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Molecular Subtypes and a Prognostic Signature Based on Inflammation-Related Genes in Colon Adenocarcinoma.
    Qiu C; Shi W; Wu H; Zou S; Li J; Wang D; Liu G; Song Z; Xu X; Hu J; Geng H
    Front Immunol; 2021; 12():769685. PubMed ID: 35003085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel signature incorporating lipid metabolism- and immune-related genes to predict the prognosis and immune landscape in hepatocellular carcinoma.
    Yang T; Luo Y; Liu J; Liu F; Ma Z; Liu G; Li H; Wen J; Chen C; Zeng X
    Front Oncol; 2023; 13():1182434. PubMed ID: 37346073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
    Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
    BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A nomogram model based on the number of examined lymph nodes-related signature to predict prognosis and guide clinical therapy in gastric cancer.
    Li H; Lin D; Yu Z; Li H; Zhao S; Hainisayimu T; Liu L; Wang K
    Front Immunol; 2022; 13():947802. PubMed ID: 36405735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer.
    Hua T; Liu DX; Zhang XC; Li ST; Yan P; Zhao Q; Chen SB
    Front Immunol; 2023; 14():1151109. PubMed ID: 37063862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Intratumor Heterogeneity-Related Signature for Predicting Prognosis, Immune Landscape, and Chemotherapy Response in Colon Adenocarcinoma.
    Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Xie Y
    Front Med (Lausanne); 2022; 9():925661. PubMed ID: 35872794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
    Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
    Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment.
    Chen J; Fu Y; Hu J; He J
    Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive
    Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
    Front Immunol; 2022; 13():931906. PubMed ID: 35958598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
    Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
    Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
    Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
    Front Oncol; 2022; 12():915662. PubMed ID: 36033441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis reveals a four-gene signature for predicting survival and immunotherapy response in colon cancer patients using bulk and single-cell RNA-seq data.
    Chai R; Zhao Y; Su Z; Liang W
    Front Oncol; 2023; 13():1277084. PubMed ID: 38023180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.